Market By Type, Industry Verticals, And Country | Forecast 2021-2028
Triton’s report reveals that the non-alcoholic steatohepatitis (NASH) biomarker market in Latin America is envisioned to witness progress at a CAGR of 21.70% during the phase 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The countries analyzed in this market include:
•       Brazil
•       Mexico
•       Rest of Latin America
In the region, supportive government policies, such as significant investments and initiatives to spread healthcare awareness, are anticipated to amplify the growth of the non-alcoholic steatohepatitis biomarker market. Additionally, the rise in the prevalence of diabetes is another factor that is estimated to supplement the studied market’s growth. For instance, over the years, there has been a tremendous rise in the number of people who have diabetes in Mexico. This number is likely to surge at an exponential rate by 2040. Here, diabetes can progress to develop non-alcoholic steatohepatitis in certain cases, which will further add to the growth of the NASH biomarker market.
On the other hand, the occurrence of obesity-related metabolic diseases has increased, leading to the rise in non-alcoholic fatty liver disease across Brazil. Moreover, the country is facing a burden of the high incidence of NASH. Several doctors are suggesting procedures to treat obesity and diabetes, which are major causes of NASH. For instance, some doctors have performed bariatric surgery for patients suffering from obesity, significantly decreasing NASH to a certain extent. Such developments in medical services are anticipated to fuel the growth of the NASH biomarker market.
Further, the prevalence of diabetes is relatively less in Brazil compared to other nations. However, the diabetes rates are rising each year, amplifying the risk of developing NASH. As reported by WHO, a significant amount of obese people suffers from diabetics in the country. Hence, as stated above, these factors are likely to augment the progress of the non-alcoholic steatohepatitis biomarker market in Brazil.
Merck & Co is a global healthcare company providing innovative healthcare solutions through its business segments, such as pharmaceutical, healthcare services, alliances, and animal health. It offers therapeutic and preventive agents to treat diabetes, asthma, and other conditions. Additionally, it offers products to prevent chemotherapy-induced postoperative nausea and vomiting. The company has operations in multiple regions, including Latin America.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
1. LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. KEY INSIGHTS
2.1.1. DEMAND FOR NASH BIOMARKERS
2.1.2. UNMET MEDICAL NEEDS
2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR LANDSCAPE
2.6. KEY MARKET STRATEGIES
2.6.1. CONTRACTS & PARTNERSHIPS
2.6.2. BUSINESS EXPANSIONS & DIVESTITURES
2.6.3. ACQUISITIONS & MERGERS
2.6.4. NEW PRODUCT LAUNCHES
2.7. MARKET DRIVERS
2.7.1. RISING PREVALENCE OF NASH
2.7.2. INCREASING INCIDENCE RATE OF METABOLIC COMORBIDITIES
2.8. MARKET RESTRAINTS
2.8.1. SIDE-EFFECTS OF NASH THERAPEUTICS
2.8.2. UNAVAILABILITY OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
2.9. MARKET OPPORTUNITIES
2.9.1. GROWTH OPPORTUNITIES IN DEVELOPING REGIONS
2.9.2. RISE IN AWARENESS PERTAINING TO NON-ALCOHOLIC FATTY LIVER DISEASE
3. LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY TYPE
3.1. SERUM BIOMARKER
3.2. HEPATIC FIBROSIS BIOMARKER
3.3. APOPTOSIS BIOMARKER
3.4. OXIDATIVE STRESS BIOMARKER
3.5. OTHER TYPES
4. LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY INDUSTRY VERTICALS
4.1. PHARMA & CRO INDUSTRY
4.2. DIAGNOSTIC LAB
4.3. ACADEMIC RESEARCH KEY
4.4. HOSPITAL
5. LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - COUNTRY OUTLOOK
5.1. MEXICO
5.2. BRAZIL
5.3. REST OF LATIN AMERICA
6. COMPETITIVE LANDSCAPE
6.1. ALLERGAN
6.2. ASTRAZENECA
6.3. BRISTOL MYERS SQUIBB COMPANY
6.4. GENFIT SA
6.5. GILEAD SCIENCES INC
6.6. MADRIGAL PHARMACEUTICALS
6.7. MERCK & CO
6.8. NOVARTIS AG
6.9. NOVO NORDISK
6.10. PFIZER INC
6.11. SIEMENS HEALTHINEERS
6.12. VIKING THERAPEUTICS
6.13. ZYDUS CADILA
7. RESEARCH METHODOLOGY & SCOPE
7.1. RESEARCH SCOPE & DELIVERABLES
7.1.1.  OBJECTIVES OF STUDY
7.1.2.  SCOPE OF STUDY
7.2. SOURCES OF DATA
7.2.1.  PRIMARY DATA SOURCES
7.2.2.  SECONDARY DATA SOURCES
7.3. RESEARCH METHODOLOGY
7.3.1.  EVALUATION OF PROPOSED MARKET
7.3.2.  IDENTIFICATION OF DATA SOURCES
7.3.3.  ASSESSMENT OF MARKET DETERMINANTS
7.3.4.  DATA COLLECTION
7.3.5.  DATA VALIDATION & ANALYSIS
TABLE 1:Â Â Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 2:Â Â Â Â Â Â VENDOR LANDSCAPE
TABLE 3:Â Â Â Â Â Â LIST OF CONTRACTS & PARTNERSHIPS
TABLE 4:Â Â Â Â Â Â LIST OF BUSINESS EXPANSIONS & DIVESTITURES
TABLE 5:Â Â Â Â Â Â LIST OF ACQUISITIONS & MERGERS
TABLE 6:Â Â Â Â Â Â LIST OF NEW PRODUCT LAUNCHES
TABLE 7:Â Â Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 8:Â Â Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 9:Â Â Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
FIGURE 1:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 2:    PORTER’S FIVE FORCES ANALYSIS
FIGURE 3:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2020 & 2028 (IN %)
FIGURE 4:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 5:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 6:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 7:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 8:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)
FIGURE 9:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)
FIGURE 10:Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)
FIGURE 11:Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)
FIGURE 12:Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)
FIGURE 13:Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)
FIGURE 14:Â MEXICO NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 15:Â BRAZIL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 16:Â REST OF LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)